343 related articles for article (PubMed ID: 17652314)
1. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
[TBL] [Abstract][Full Text] [Related]
2. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.
Hoeper MM; Leuchte H; Halank M; Wilkens H; Meyer FJ; Seyfarth HJ; Wensel R; Ripken F; Bremer H; Kluge S; Hoeffken G; Behr J
Eur Respir J; 2006 Oct; 28(4):691-4. PubMed ID: 17012628
[TBL] [Abstract][Full Text] [Related]
3. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
Molnar C; Alber H; Colleselli D; Vogel W; Kähler CM
Wien Klin Wochenschr; 2004 Sep; 116(17-18):627-30. PubMed ID: 15515882
[TBL] [Abstract][Full Text] [Related]
4. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
Dandel M; Lehmkuhl HB; Mulahasanovic S; Weng Y; Kemper D; Grauhan O; Knosalla C; Hetzer R
J Heart Lung Transplant; 2007 Sep; 26(9):898-906. PubMed ID: 17845928
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
Halank M; Kolditz M; Miehlke S; Schiemanck S; Schmeisser A; Hoeffken G
Wien Med Wochenschr; 2005 Aug; 155(15-16):376-80. PubMed ID: 16160926
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
8. Bosentan therapy for portopulmonary hypertension.
Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of portopulmonary hypertension with bosentan: case report.
Stähler G; von Hunnius P
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():62-6. PubMed ID: 16919013
[TBL] [Abstract][Full Text] [Related]
10. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan.
Fruhwald FM; Kjellström B; Perthold W; Wonisch M; Maier R; Klein W
J Heart Lung Transplant; 2005 May; 24(5):631-4. PubMed ID: 15896766
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
[TBL] [Abstract][Full Text] [Related]
13. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
Hoeper MM; Taha N; Bekjarova A; Gatzke R; Spiekerkoetter E
Eur Respir J; 2003 Aug; 22(2):330-4. PubMed ID: 12952269
[TBL] [Abstract][Full Text] [Related]
14. Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost.
Ahmadi-Simab K; Lamprecht P; Gross WL
Clin Exp Rheumatol; 2005; 23(3):402-3. PubMed ID: 15971433
[TBL] [Abstract][Full Text] [Related]
15. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Hoeper MM; Markevych I; Spiekerkoetter E; Welte T; Niedermeyer J
Eur Respir J; 2005 Nov; 26(5):858-63. PubMed ID: 16264047
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.
Savale L; Magnier R; Le Pavec J; Jaïs X; Montani D; O'Callaghan DS; Humbert M; Dingemanse J; Simonneau G; Sitbon O
Eur Respir J; 2013 Jan; 41(1):96-103. PubMed ID: 22653773
[TBL] [Abstract][Full Text] [Related]
17. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension.
Melgosa MT; Ricci GL; García-Pagan JC; Blanco I; Escribano P; Abraldes JG; Roca J; Bosch J; Barberà JA
Liver Transpl; 2010 Mar; 16(3):348-56. PubMed ID: 20209595
[TBL] [Abstract][Full Text] [Related]
18. Endothelin and endothelin receptor antagonism in portopulmonary hypertension.
Neuhofer W; Gülberg V; Gerbes AL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():54-61. PubMed ID: 16919012
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
[TBL] [Abstract][Full Text] [Related]
20. [Portopulmonary hypertension].
Halank M; Miehlke S; Kolditz M; Hoeffken G
Z Gastroenterol; 2005 Jul; 43(7):677-85. PubMed ID: 16001350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
